Physician profile
Andrew Ebner
NPI 1225709280
$2,845.39
in general payments reported to CMS, 2019-2025
14 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $442 · 2024: $580 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.03 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $764.17 | 2022-2025 | Caplyta |
| Alkermes, INC. | $497.37 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $344.50 | 2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $227.05 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $221.13 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $180.59 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $172.57 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $153.43 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $90.47 | 2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $58.14 | 2024-2025 | Auvelity |
| Lundbeck LLC | $57.17 | 2024-2025 | Abilify Maintena, Rexulti |
| Noven Therapeutics, LLC | $37.86 | 2025 | Xelstrym |
| Almatica Pharma LLC | $22.95 | 2025 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.99 | 2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ebner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.